期刊
GERONTOLOGY
卷 60, 期 4, 页码 289-293出版社
KARGER
DOI: 10.1159/000356740
关键词
Aging; Frailty; Skeletal muscle; Atrophy; Growth and differentiation factor; Drug discovery; Obesity; Diabetes
资金
- Mayo Clinic Center for Cell Signaling in Gastroenterology [NIDDK P30DK084567]
- Mayo Clinic
The progressive loss of skeletal muscle mass, strength and/or function with advancing age, termed sarcopenia, poses a major threat to independence and quality of life. Therefore, there is significant merit in better understanding the biology of sarcopenia and developing therapeutic interventions to prevent, slow or reverse its progression. Since the discovery of nnyostatin, a potent negative regulator of growth that is highly enriched in skeletal muscle, there has been great interest in it as a potential mediator of sarcopenia as well as a therapeutic target. The complex biology of myostatin, the promise of myostatin inhibition as an effective means to counter sarcopenia, and the challenges facing its clinical translation are reviewed herein. (C) 2014 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据